Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 17/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23674420 | 0.84 | NLRP3 (0.34) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL23674468 | 0.76 | ALDH1A1 (0.36) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL25404709 | 0.75 | NLRP3 (0.40) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL30852987 | 0.72 | NLRP3 (0.63) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL20412501 | 0.72 | NLRP3 (0.51) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL21646719 | 0.71 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL19505705 | 0.71 | NLRP3 (0.46) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL22705175 | 0.71 | NLRP3 (0.39) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL20635326 | 0.71 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL20713466 | 0.71 | NLRP3 (0.54) | NLRP3ALDH1A1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783184-A | Sulfamoylurea derivatives containing alkyl-oxacycloalkyl moieties and uses thereof | 诺瑟拉有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023037024-A1 | N-SULFONYLUREA DERIVATIVES AND THE THERAPEUTIC USE THEREOF | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (90%) (ES) | 2023-03-16 | — | — | WO | disclosed |
| CN-115605209-A | NLRP3 modulators | 祖玛珍生物科学有限公司（GB） | 2023-01-13 | — | — | CN | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| WO-2021150574-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | NLRP3 1/4885ALDH1A1 3558/4885ATM 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.